Li Nan, Li Xu, Cheng Peng, Yang Ping, Shi Pengcheng, Kong Lingyu, Liu Hongbin
Pharmaceutical Analysis Center of Tianjin Institute of Medical and Pharmaceutical Sciences, 79 Duolun Road, Heping District, Tianjin 300020, China.
Cardiovascular and Cerebrovascular Drugs Research and Development Center of Tianjin Institute of Medical and Pharmaceutical Sciences, 79 Duolun Road, Heping District, Tianjin 300020, China.
Evid Based Complement Alternat Med. 2021 Oct 28;2021:4828169. doi: 10.1155/2021/4828169. eCollection 2021.
The purpose of this study is to design a flower-shaped lactose loaded curcumin solid lipid nanoparticles dry powder inhaler and characterize it to improve the solubility and dissolution rate of curcumin in lung. Curcumin solid lipid nanoparticles (Cur-SLNs) were prepared by solvent evaporation method, and then they were micronized by freeze-drying technology. Finally, Cur-SLN micropowder obtained by freeze-drying was mixed with flower-shaped lactose (FL) at a ratio of 2 : 1 and then passed through a 200-mesh sieve to obtain Cur-SLN-FL powder. Tween-80 was selected as the surfactant to inhibit the aggregation of drug solid lipid nanoparticles. Under the optimum conditions, the solid lipid nanoparticles (SLN) were relatively spherical, with an average particle size of 14.7 nm, narrow distribution, Zeta potential of -22.5 mV, encapsulation efficiency of 90.21%, and drug loading of 8.56%. According to the particle size, PI, Zeta potential, drug loading (LC%), encapsulation efficiency (EE%), morphology, and in vitro release characteristics, the prescription of solid lipid nanoparticles was screened. Dry powder inhaler (DPI) was characterized by differential scanning calorimetry, scanning electron microscopy, particle size, density, and in vitro release performance. Its cytotoxicity to mouse fibroblasts (L929) and human normal lung epithelial cells (BEAS-2B) in vitro was investigated, and its safety for pulmonary inhalation was preliminarily determined. FTIR analysis shows that the micronized Cur-SLN-FL has the same chemical structure as FL. FTIR and DSC analysis confirmed that the characteristic absorption peak of curcumin was not found in Cur-SLN-FL, showing similar structure to SLN and FL. In addition, curcumin was coated in solid lipid nanoparticles to make powder mist, which increased its drug loading, kept its aerodynamic particle size (4.03 ± 0.40) m, and significantly improved its drug release performance in artificial lung fluid. In vitro cytotoxicity test results confirmed that Cur-SLN-FL was less toxic to BEAS-2B cells than L929 cells. Therefore, curcumin was prepared into solid lipid nanoparticles by emulsion evaporation-low temperature solidification method and then micronized and mixed with FL to prepare curcumin solid lipid nanoparticle powder mist loaded with flower-shaped lactose. The process is simple and feasible, and it has better safety performance for lung cells, which is expected to become a safe and effective delivery system for pulmonary inhalation drugs.
本研究的目的是设计一种花形乳糖负载姜黄素固体脂质纳米粒干粉吸入器,并对其进行表征,以提高姜黄素在肺部的溶解度和溶解速率。采用溶剂蒸发法制备姜黄素固体脂质纳米粒(Cur-SLNs),然后通过冷冻干燥技术将其微粉化。最后,将冷冻干燥得到的Cur-SLN微粉与花形乳糖(FL)按2∶1的比例混合,过200目筛,得到Cur-SLN-FL粉末。选择吐温80作为表面活性剂以抑制药物固体脂质纳米粒的聚集。在最佳条件下,固体脂质纳米粒(SLN)呈相对球形,平均粒径为14.7nm,分布窄,Zeta电位为-22.5mV,包封率为90.21%,载药量为8.56%。根据粒径、PI、Zeta电位、载药量(LC%)、包封率(EE%)、形态和体外释放特性,筛选固体脂质纳米粒的处方。通过差示扫描量热法、扫描电子显微镜、粒径、密度和体外释放性能对干粉吸入器(DPI)进行表征。研究了其对小鼠成纤维细胞(L929)和人正常肺上皮细胞(BEAS-2B)的体外细胞毒性,并初步确定其肺部吸入的安全性。傅里叶变换红外光谱(FTIR)分析表明,微粉化的Cur-SLN-FL与FL具有相同的化学结构。FTIR和差示扫描量热法(DSC)分析证实,Cur-SLN-FL中未发现姜黄素的特征吸收峰,其结构与SLN和FL相似。此外,姜黄素被包裹在固体脂质纳米粒中制成粉末雾剂,增加了其载药量,使其空气动力学粒径保持在(4.03±0.40)μm,并显著提高了其在人工肺液中的药物释放性能。体外细胞毒性试验结果证实,Cur-SLN-FL对BEAS-2B细胞的毒性小于对L929细胞的毒性。因此,采用乳化蒸发-低温固化法将姜黄素制备成固体脂质纳米粒,然后微粉化并与FL混合,制备了花形乳糖负载姜黄素固体脂质纳米粒粉末雾剂。该工艺简单可行,对肺细胞具有较好的安全性能,有望成为一种安全有效的肺部吸入药物递送系统。